Molecular profiling in diffuse large B‐cell lymphoma: why so many types of subtypes?

Summary The term diffuse large B‐cell lymphoma (DLBCL) includes a heterogeneous collection of biologically distinct tumours. This heterogeneity currently presents a barrier to the successful deployment of novel, biologically targeted therapies. Molecular profiling studies have recently proposed new...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2022-02, Vol.196 (4), p.814-829
Main Authors: Morin, Ryan D., Arthur, Sarah E., Hodson, Daniel J.
Format: Article
Language:English
Subjects:
B-cell lymphoma
cancer genetics
Classification systems
classifications
Clinical trials
diffuse large B‐cell lymphoma
Discordance
Gene Expression Profiling - methods
Genomics - methods
Hematology
Humans
Lymphoma
Lymphoma, Large B-Cell, Diffuse - genetics
lymphomas
mutation analysis
Precision medicine
Prognosis
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary The term diffuse large B‐cell lymphoma (DLBCL) includes a heterogeneous collection of biologically distinct tumours. This heterogeneity currently presents a barrier to the successful deployment of novel, biologically targeted therapies. Molecular profiling studies have recently proposed new molecular classification systems. These have the potential to resolve the biological heterogeneity of DLBCL into manageable subgroups of tumours that rely on shared oncogenic programmes. In many cases these biological programmes straddle the boundaries of our existing systems for classifying B‐cell lymphomas. Here we review the findings from these major molecular profiling studies with a specific focus on those that propose new genetic subgroups of DLBCL. We highlight the areas of consensus and discordance between these studies and discuss the implications for current clinical practice and for clinical trials. Finally, we address the outstanding challenges and solutions to the introduction of genomic subtyping and precision medicine in DLBCL.
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.17811